Lixte Biotechnology Holdings, Inc. Sample Contracts
COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC.Security Agreement • July 20th, 2023 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ___________or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on July 20, 2028 (the “Termination Date”), but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to [●] common shares, par value $0.0001 per share (the “Common Stock”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC.Common Stock Purchase Warrant • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [__] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [__], 2024 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [__], 2029 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to [__] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRE-FUNDED COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINDS, INC.Pre-Funded Common Stock Purchase Warrant • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [__] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), up to [__] (as subject to adjustment hereunder, the “Warrant Shares”) of the common stock, par value $0.0001 per share, of the Company (“Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 13th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 11, 2025, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 8th, 2006 • SRKP 7 Inc • Blank checks
This Registration Rights Agreement (this “Agreement”) is made and entered into as of _______________, 2006, by and among SRKP 7, Inc., a Delaware corporation (the “Company”), on the one hand, and the purchasers signatory hereto (each such purchaser, a “Purchaser” and collectively, the “Purchasers”) and those shareholders of the Company listed on Exhibit A (the “Shareholders”), on the other hand.
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Lixte Biotechnology Holdings, Inc.Placement Agent Agreement • February 13th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on February 11, 2030 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). The Warrants are issued pursuant to that certain engagement letter, dated as of February 5, 2025, by and between the Company and H.C. Wainwright & Co., LLC.
COMMON STOCK PURCHASE WARRANT Lixte Biotechnology Holdings, Inc.Common Stock Purchase Agreement • February 13th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ______________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
LIXTE BIOTECHNOLOGY HOLDINGS, INC. COMMON STOCK SALES AGREEMENTSales Agreement • September 20th, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with WestPark Capital, Inc., as follows:
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 20th, 2023 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of July [18], 2023, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
LIXTE BIOTECHNOLOGY HOLDINGS, INC. INDENTURE Dated as of __________, 20___Indenture • January 26th, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
Each party agrees as follows for the benefit of the other party and for the equal and ratable benefit of the Holders of the Securities issued under this Indenture.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 3rd, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of June 30, 2025, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each, a “Purchaser” and collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 2nd, 2021 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February 26, 2021, and is between Lixte Biotechology Holdings,, Inc, a corporation incorporated under the laws of the state of Delaware (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • June 8th, 2006 • SRKP 7 Inc • Blank checks • New York
AGREEMENT entered into as of the 17th day of May, 2006, by and between SRKP 7, Inc., a Delaware corporation with an address at 1900 Avenue of the Stars, Suite 310, Los Angeles, CA 90067 (the “Company”) and TMC Ulster Holdings Inc., a New York corporation with an address at 86 Ponche Terrace, Showkan, New York 12481 (the “Purchaser”).
LIXTE Biotechnology Holdings, Inc. Common Stock (par value $0.0001 per share) At-The-Market Issuance Sales AgreementAt-the-Market Issuance Sales Agreement • January 6th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with WallachBeth Capital LLC (the “Agent”), as follows:
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT 1,200,000 Units Consisting of 1,200,000 Shares of Common Stock And 1,200,000 Warrants to Purchase 1,200,000 Shares of Common StockUnderwriting Agreement • November 27th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. and WallachBeth Capital, LLC are acting as representatives (the “Representatives”), an aggregate of 1,200,000 Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The 1,200,000 shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privil
Placement Agency AgreementPlacement Agency Agreement • November 1st, 2024 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
PIPE PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC.Security Agreement • July 3rd, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time until this Warrant is exercised in full (the “Termination Date”), to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to [●] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. Subject to the provisions of Section 2.3, the purchase price of one (1) share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2.2.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 4th, 2026 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 2, 2026, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”).
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT [*] Units Consisting of [*] Shares of Common Stock And [*] Warrants to Purchase [*] Shares of Common StockUnderwriting Agreement • November 16th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. is acting as representative (the “Representative”), an aggregate of [__] Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The [__] shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privileges set forth in, a warrant agent agreeme
WARRANT AGENT AGREEMENTWarrant Agent Agreement • November 27th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Warrant Agent Agreement (“Warrant Agreement”) is made as of November 30, 2020, by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation, with offices at 248 Route 25A, No.22 East Setauket, NY 11733 (the “Company”), and Computershare Inc., a Delaware corporation, and its wholly-owned subsidiary Computershare Trust Company N.A. a federally chartered trust company (collectively, the “Warrant Agent”).
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT [*] Shares of Common StockUnderwriting Agreement • October 13th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. is acting as representative (the “Representative”), an aggregate of [*] authorized but unissued shares of common stock, par value $0.0001 per share, (the “Common Stock”) of the Company (the “Firm Shares”). The Company also proposes to sell to the Underwriters, upon the terms and conditions set forth in Section 4 hereof, up to an additional [*] shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter collectively referred to as the “Shares” or the “Securities”.
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • December 22nd, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of [_______], between [________] (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 18th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
This Employment Agreement (“Agreement”) is entered into as of August 12, 2020 by and between Lixte Biotechnology Holdings Inc., a Delaware corporation having its principal place of business located at 248 Route 25A, No. 2, East Setauket, NY 11733 (“Company”), and Robert N. Weingarten (“Employee”), an individual residing at 5439 Lockhurst Dr., Woodland Hills, CA 91367.
UNDERWRITING AGREEMENTUnderwriting Agreement • June 18th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • April 10th, 2017 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT this (“Agreement”), dated as of April 3, 2017, by and among Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and Hung Tak Ho (“Purchaser”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 8th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of July 3, 2025, between Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each, a “Purchaser” and collectively, the “Purchasers”).
SERVICES AGREEMENT between LIXTE BIOTECHNOLOGY, INC. and Freestate of Bavaria Represented by UNIVERSITY OF REGENSBURG for its Institute of Pathology, Franz- Josef-Strauss-Alle 11, D-93053 RegensburgServices Agreement • March 13th, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks
This Agreement is made as of the 5th day of January, 2007 (the “Effective Date”), between Lixte Biotechnology, Inc., a Delaware corporation having its principal place of business at 248 Route 25A #2, East Setauket, New York 11733, United States of America (“Lixte”), and The Free State of Bavaria, represented by the University of Regensburg, a German entity having its principal place of business at 93040 Regensburg, Germany, in turn represented by the Head of Administration (“University”).
UNDERWRITER WARRANT TO PURCHASE COMMON STOCK LIXTE BIOTECHNOLOGY HOLDINGS, INC.Purchase Warrant Agreement • June 18th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, in consideration of funds duly paid by or on behalf of Spartan Capital Securities, LLC (“Holder”), as registered owner of this Purchase Warrant, to Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), Holder is entitled, at any time or from time to time beginning [●]5 (the “Commencement Date”), and at or before 5:00 p.m., Eastern time, on [●], 2025 (the “Expiration Date”), but not thereafter, to subscribe for, purchase and receive, in whole or in part, up to [●] shares of Common Stock, $0.0001 par value per share (the “Shares”), subject to adjustment as provided in Section 5 hereof. If the Expiration Date is not a Trading Day, then this Purchase Warrant may be exercised on the next succeeding Trading Day. During the period beginning on [●], 2025 and ending on the Expiration Date, the Company agrees not to take any action that would terminate this Purchase Warrant. This Purchase Warrant is initi
STOCK OPTION AGREEMENTStock Option Agreement • November 14th, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks • Delaware
THIS STOCK OPTION AGREEMENT (“Agreement”) is made by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC, a Delaware corporation (the “Company”), and FRANCIS JOHNSON (the “Optionee”).
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • December 30th, 2015 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS AGREEMENT is made and entered into as of December 25, 2015 (hereinafter “EFFECTIVE DATE”) by and between Lixte Biotechnology Holdings, Inc. a Delaware corporation, whose address is 248 Route 25A, No. 2, East Setauket, NY 11733 (hereinafter “LICENSOR”) and Taipei Medical University, an institution with a place of business at 250 Wuxing Street, Taipei City, Taiwan 110 ((hereinafter “LICENSEE”).
STOCK OPTION AGREEMENTStock Option Agreement • November 14th, 2007 • Lixte Biotechnology Holdings, Inc. • Blank checks • Delaware
THIS STOCK OPTION AGREEMENT (“Agreement”) is made by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC, a Delaware corporation (the “Company”), and STEPHEN K. CARTER (the “Optionee”).
SHARE EXCHANGE AGREEMENTShare Exchange Agreement • November 25th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
This Share Exchange Agreement (this “Agreement”), dated as of November 21, 2025, is entered into by and among Orbit Capital Inc., a Cayman Islands corporation (the “Seller”), Liora Technologies Europe Ltd., a corporation organized under the laws of England and Wales which is wholly-owned by the Seller (the “Company”), and Lixte Biotechnology Holdings, Inc., a Delaware corporation (“PubCo”).
Collaboration Agreement between the Company and BioPharmaWorks LLCCollaboration Agreement • September 18th, 2015 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AGREEMENT (this “Agreement”) is made and entered into as of September __, 2015 (the “Effective Date”), by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation (“Lixte”) and BioPharmaWorks LLC, a Connecticut limited liability company (“BioPharma”) with reference to the following:
EMPLOYMENT AGREEMENTEmployment Agreement • June 17th, 2025 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • Delaware
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is by and between LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), with an address of 680 East Colorado Boulevard, Suite 180, Pasadena, California 91101, and Geordan Pursglove, an individual (the “Employee”), with an address of 222 Yamato Road, Suite 260, Boca Raton, Florida 33431, and shall be deemed effective as of June 16, 2025 (the “Effective Date”).